STAT Plus: After years of manufacturing problems, Akorn files for bankruptcy protection
After mounting financial and manufacturing woes, Akorn (AKRX) has filed for bankruptcy protection, a humbling move by a company that was on the verge of being purchased for $4.3 billion just two years ago.
The filing follows a protracted period in which the drug maker haggled with lenders and fended off shareholder lawsuits, which were prompted after Fresenius Kabi walked away from a deal to buy the company. The acquisition fell apart after Fresenius found what it described as “material breaches” in manufacturing standards at Akorn facilities.
Continue to STAT Plus to read the full story…
